Trial Profile
Phase 1 Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Soft Tissue Sarcoma and Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; REC 2282 (Primary)
- Indications Renal cell carcinoma; Soft tissue sarcoma
- Focus Adverse reactions
- 01 Apr 2019 Status changed from active, no longer recruiting to discontinued.
- 31 Jan 2018 Status changed from suspended to active, no longer recruiting.
- 03 Mar 2017 Planned End Date changed from 1 Jun 2025 to 30 Jun 2025.